Source 1primary paper2025MED
Toolkit/LV_EF1α_GBA_Opt
LV_EF1α_GBA_Opt
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
A functional lentiviral vector, LV_EF1α_GBA_Opt, was generated at a titer of 7.88 × 108 LV particles/mL as determined by qPCR.
Usefulness & Problems
Why this is useful
This lentiviral construct encodes a codon-optimized GCase gene under the hEF1α promoter and was used to establish stable human producer cells with elevated GCase activity. The abstract presents it as the core engineered vector of the study.; stable production of recombinant GCase in human cell lines; in vitro generation of high-activity GCase-producing producer cells
Source:
This lentiviral construct encodes a codon-optimized GCase gene under the hEF1α promoter and was used to establish stable human producer cells with elevated GCase activity. The abstract presents it as the core engineered vector of the study.
Source:
stable production of recombinant GCase in human cell lines
Source:
in vitro generation of high-activity GCase-producing producer cells
Problem solved
It addresses low production efficiency for recombinant GCase by enabling stable expression in human cells. The paper frames this as relevant to reducing barriers associated with costly enzyme replacement therapy.; improving production efficiency for recombinant GCase
Source:
It addresses low production efficiency for recombinant GCase by enabling stable expression in human cells. The paper frames this as relevant to reducing barriers associated with costly enzyme replacement therapy.
Source:
improving production efficiency for recombinant GCase
Problem links
improving production efficiency for recombinant GCase
LiteratureIt addresses low production efficiency for recombinant GCase by enabling stable expression in human cells. The paper frames this as relevant to reducing barriers associated with costly enzyme replacement therapy.
Source:
It addresses low production efficiency for recombinant GCase by enabling stable expression in human cells. The paper frames this as relevant to reducing barriers associated with costly enzyme replacement therapy.
Published Workflows
Objective: Establish stable human cell lines for high-yield in vitro production of biologically active synthetic recombinant GCase using a lentiviral system.
Why it works: The abstract states that codon optimization, lentiviral delivery, and clonal selection together enable establishment of stable human cell lines producing high levels of biologically active recombinant GCase.
codon-optimized GCase expressionhEF1α-driven transgene expressionstable lentiviral integrationclonal enrichment of high-producing cellslentiviral vector generationrepeated transductionsingle-cell cloningqPCR titer measurementenzyme activity screening
Stages
- 1.Lentiviral vector generation and titering(library_build)
This stage creates the delivery construct needed for stable transduction of human cells.
Selection: Generate a functional lentiviral vector carrying codon-optimized GCase and confirm production by qPCR titer.
- 2.Repeated transduction of human cells(broad_screen)
This stage establishes a transduced heterogeneous producer population before clonal isolation.
Selection: Introduce the lentiviral construct into human cells through six transduction cycles at MOI 30-50 and assess activity in the heterogeneous population.
- 3.Single-cell cloning and clone characterization(hit_picking)
This stage narrows the heterogeneous population to higher-producing clones.
Selection: Isolate single-cell-derived clones and identify those with the highest GCase-specific activity.
Steps
- 1.Generate LV_EF1α_GBA_Opt lentiviral vectorengineered construct
Create a functional lentiviral vector encoding codon-optimized GCase for stable production in human cells.
The delivery construct must exist before cells can be transduced.
- 2.Measure lentiviral titer by qPCRvector being quantified
Confirm that the generated lentiviral vector is functional and quantify viral stock concentration.
Titer measurement verifies the vector stock before repeated transduction of target cells.
- 3.Perform six transduction cycles at MOI 30-50delivery construct
Establish a transduced heterogeneous human cell population for stable GCase production.
Cells must first be transduced before population-level enzyme activity can be assessed and before clone isolation.
- 4.Measure GCase-specific activity in the heterogeneous transduced populationconstruct being evaluated through producer-cell output
Determine whether the transduced population shows improved GCase production relative to wild-type cells.
Population-level activity is assessed before single-cell cloning to confirm that the engineered system improved output.
- 5.Isolate single-cell clones from the transduced population
Separate the heterogeneous producer population into individual clones for higher-resolution identification of top producers.
Clonal isolation follows confirmation that the heterogeneous population has elevated activity and is used to enrich for the best producers.
- 6.Identify high-activity clones by specific activity measurementconstruct evaluated through clone performance
Find individual clones with the highest GCase-specific activity.
After clonal isolation, clone-level activity testing provides a higher-fidelity readout than the heterogeneous population average.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
Selection / EnrichmentTarget processes
recombinationselectionImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: regulator
Its use requires lentiviral production, transduction of human cell lines, and downstream single-cell cloning to isolate high-producing clones. qPCR was used to quantify vector titer.; requires lentiviral vector generation; uses a codon-optimized GCase gene under the hEF1α promoter; used repeated transduction cycles at MOI 30-50; used single-cell cloning to isolate higher-producing clones
The abstract does not show therapeutic validation in patient-derived fibroblasts or animal models. It also does not establish downstream therapeutic suitability beyond in vitro biological activity.; functional validation in GD patient-derived fibroblasts and animal models was not yet reported in the abstract
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Transduced heterogeneous human cells showed higher GCase-specific activity than wild-type 293FT cells.
The transduced heterogeneous human cell population showed GCase-specific activity of 307.5 ± 53.49 nmol/mg protein/h, which represents a 3.21-fold increase compared to wild-type 293FT cells (95.58 ± 16.5 nmol/mg protein/h).
fold increase versus wild-type 293FT 3.21GCase-specific activity 307.5 nmol/mg protein/hGCase-specific activity 95.58 nmol/mg protein/h
Single-cell cloning identified clones with substantially higher GCase-specific activity than the heterogeneous transduced population.
Following single-cell cloning, two clones showed specific activity of 763.8 ± 135.1 and 752.0 ± 152.1 nmol/mg/h (clones 15 and 16, respectively).
GCase-specific activity 763.8 nmol/mg/hGCase-specific activity 752 nmol/mg/h
Codon optimization, lentiviral delivery, and clonal selection together enabled establishment of stable human cell lines producing high levels of biologically active synthetic recombinant GCase in vitro.
These results show that codon optimization, a lentiviral delivery system, and clonal selection together enable the establishment of stable human cell lines capable of producing high levels of biologically active, synthetic recombinant GCase in vitro.
The study developed a lentiviral system encoding a codon-optimized GCase gene driven by the hEF1α promoter for stable production in human cell lines.
we developed a lentiviral system encoding a codon-optimized GCase gene driven by the human elongation factor 1a (hEF1α) promoter for stable production in human cell lines
LV_EF1α_GBA_Opt was generated at a lentiviral titer of 7.88 × 10^8 particles/mL by qPCR.
A functional lentiviral vector, LV_EF1α_GBA_Opt, was generated at a titer of 7.88 × 108 LV particles/mL as determined by qPCR.
lentiviral titer 788000000 LV particles/mL
Approval Evidence
1 source5 linked approval claimsfirst-pass slug lv-ef1-gba-opt
A functional lentiviral vector, LV_EF1α_GBA_Opt, was generated at a titer of 7.88 × 108 LV particles/mL as determined by qPCR.
Source:
activity increasesupports
Transduced heterogeneous human cells showed higher GCase-specific activity than wild-type 293FT cells.
The transduced heterogeneous human cell population showed GCase-specific activity of 307.5 ± 53.49 nmol/mg protein/h, which represents a 3.21-fold increase compared to wild-type 293FT cells (95.58 ± 16.5 nmol/mg protein/h).
Source:
clonal enrichmentsupports
Single-cell cloning identified clones with substantially higher GCase-specific activity than the heterogeneous transduced population.
Following single-cell cloning, two clones showed specific activity of 763.8 ± 135.1 and 752.0 ± 152.1 nmol/mg/h (clones 15 and 16, respectively).
Source:
combined design logicsupports
Codon optimization, lentiviral delivery, and clonal selection together enabled establishment of stable human cell lines producing high levels of biologically active synthetic recombinant GCase in vitro.
These results show that codon optimization, a lentiviral delivery system, and clonal selection together enable the establishment of stable human cell lines capable of producing high levels of biologically active, synthetic recombinant GCase in vitro.
Source:
engineering outcomesupports
The study developed a lentiviral system encoding a codon-optimized GCase gene driven by the hEF1α promoter for stable production in human cell lines.
we developed a lentiviral system encoding a codon-optimized GCase gene driven by the human elongation factor 1a (hEF1α) promoter for stable production in human cell lines
Source:
vector titersupports
LV_EF1α_GBA_Opt was generated at a lentiviral titer of 7.88 × 10^8 particles/mL by qPCR.
A functional lentiviral vector, LV_EF1α_GBA_Opt, was generated at a titer of 7.88 × 108 LV particles/mL as determined by qPCR.
Source:
Comparisons
Source-stated alternatives
The upstream summary notes nearby alternatives such as CMV-promoter constructs, transient expression approaches, and non-mammalian production platforms, but the abstract itself does not directly compare them experimentally.
Source:
The upstream summary notes nearby alternatives such as CMV-promoter constructs, transient expression approaches, and non-mammalian production platforms, but the abstract itself does not directly compare them experimentally.
Source-backed strengths
supports stable production in human cell lines; reported high lentiviral titer; associated with increased GCase-specific activity after transduction and clonal selection
Source:
supports stable production in human cell lines
Source:
reported high lentiviral titer
Source:
associated with increased GCase-specific activity after transduction and clonal selection
Compared with inkube
LV_EF1α_GBA_Opt and inkube address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection
Compared with synthetic promoters
LV_EF1α_GBA_Opt and synthetic promoters address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection
Relative tradeoffs: appears more independently replicated; looks easier to implement in practice.
Compared with transcription factor-based biosensors
LV_EF1α_GBA_Opt and transcription factor-based biosensors address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection
Ranked Citations
- 1.